Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis

Journal of Rheumatology

Volumn 23, Issue SUPPL. 44, 1996, Pages 86-90

  Furst, Daniel E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Combination DMARD; DCART; RA

Indexed keywords

AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN; GOLD SALT; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; ANTIRHEUMATIC AGENT;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; PHARMACOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0029966484     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Pincus T, Callahan LF, Sale WG, et al: Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;21:864-72.
2. Van der Heijde DMFM, van Riel PLCM, van Rijswijk MH. van de Putte LBA: Influence of prognostic features on the final outcome in RA: A review of the literature. Semin Arthritis Rheum 1988;17:284-92.
3. Erhardt CC, Mumford PA, Venables PJW, Maini RN: Factors predicting a poor life prognosis in RA. An eight year prospective study. Ann Rheum Dis 1989;48:7-13.
4. Furst DE: Predictors of worsening clinical variables and outcomes in rheumatoid arthritis. Rheum Dis Clin North Am 1994;20:309-19.
5. Gough A, Faint J, Salmon M, et al: Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994;37:1166-70.
6. Day RO: SAARDS-I. In: Klippel JH, Dieppe PA, eds. Rheumatology. St. Louis: Mosby, 1994;8:12.1-12.10.
7. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: Results of two meta-analyses. Arthritis Rheum 1990;33:1449-61.
8. Furst DE, Clements PJ: SAARDS-II. In: Klippel JH, Dieppe PA, eds. Rheumatology. St. Louis: Mosby, 1994;8:13.1-13.8.
9. Furst DE, Weinblatt ME, eds. In: Immunomodulators in the Rheumatoid Diseases. New York: Marcel Dekker, 1990:1-98.
10. Paulus HE, Furst DE, Dromgoole SH, eds. In: Drugs for Rheumatic Diseases. New York: Churchill Livingstone, 1987:85-202.
11. Wilkens RF, Urowitz MD, Stahlen DM, et al: Comparison of azathioprine, methotrexate and the combination of both in the treatment of rheumatoid arthritis: A controlled trial. Arthritis Rheum 1992;35:849-56.
12. Tugwell P, Pincus T, Yocum D, et al: A multi-centre, double-blind, randomized trial of low-dose cyclosporin and placebo therapy in combination with methotrexate in patients with severe RA (abstr). Arthritis Rheum 1994;(suppl)37:S361
13. Williams HJ, Ward JR, Reading JC, et al: Comparison of auranofin, methotrexate and the combination of both in the treatment of RA. Arthritis Rheum 1992;35:259-69.
14. Fries JF, Singh G, Lenert L, Furst DE: Aspirin, hydroxychloroquine and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990;33:1611-9.
15. Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM: Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 1984;27:267-76.
16. Furst DE: Cyclosporine, leflunomide and nitrogen mustard. In: Brooks PM, Furst DE, guest editors. Bailliere's Clin Rheumatol 1995;9:711-30.